Stunning Breakthrough in Advanced HCC: SGN1 Extends Survival Beyond 50 Months in Patients After Second-Line Failure!
Guangzhou Sinogen Pharmaceutical (also known as “Hua Jin”) is proud to announce the ongoing progress in our clinical trials for hepatocellular carcinoma (HCC) with our innovative biological drug, SGN1. This innovative drug is at the forefront of our efforts to address significant unmet medical needs in cancer treatment. Multiple hospitals across mainland China, China Taiwan, and the US are actively participating in our trials.
We are pleased to report some encouraging results from the ongoing IND trials and an investigator-initiated (IIT) clinical study, where a total of 6 HCC recurrent patients who have received at least two lines of SOC were enrolled. One patient achieved Complete Response (CR), and two achieved Partial Response (PR), with survival times of 50 months, 11 months, and 6.5 months, respectively. In addition, one patient whose HCC lesion achieved stable (SD) condition, and is still receiving ongoing treatment with an expected PFS duration of at least 10 months. To put this in perspective, the median survival for HCC patients after failing second-line treatments is typically 8-12 months. These results reflect the potential of SGN1 to improve patient outcomes significantly.
Guangzhou Sinogen remains dedicated to developing first-in-class therapies for HCC and other aggressive malignancies. Stay tuned for further updates as we advance our Phase IIa trials for both HCC, pancreatic cancer, and sarcoma.
<END>